Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway.

@article{Li2014AutophagyBS,
  title={Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway.},
  author={Yangling Li and Peihua Luo and Jincheng Wang and Jiabin Dai and Xiaochun Yang and Honghai Wu and Bo Yang and Qiaojun He},
  journal={Toxicology and applied pharmacology},
  year={2014},
  volume={274 2},
  pages={319-27}
}
Combretastatin A-4 (CA-4) has already entered clinical trials of solid tumors over ten years. However, the limited anticancer activity and dose-dependent toxicity restrict its clinical application. Here, we offered convincing evidence that CA-4 induced autophagy in various cancer cells, which was demonstrated by acridine orange staining of intracellular acidic vesicles, the degradation of p62, the conversion of LC3-I to LC3-II and GFP-LC3 punctate fluorescence. Interestingly, CA-4-mediated… CONTINUE READING